Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.59)
# 221
Out of 5,090 analysts
66
Total ratings
63.83%
Success rate
21.2%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $14.75 | +35.59% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $73.62 | +3.23% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $10.93 | +28.09% | 1 | Aug 4, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $28.86 | +7.42% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $17.77 | -49.35% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $32.30 | +2.17% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $164.98 | +15.17% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $100.79 | -0.78% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $20.23 | -6.08% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $394.81 | -1.22% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $76.66 | -28.25% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $102.02 | -46.09% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $145.49 | +9.97% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $572.77 | +16.98% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $7.09 | +182.09% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,414.86 | -1.05% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.39 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $48.03 | +87.38% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $226.25 | +19.34% | 4 | Dec 20, 2023 |
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $14.75
Upside: +35.59%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $73.62
Upside: +3.23%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $10.93
Upside: +28.09%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $28.86
Upside: +7.42%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $17.77
Upside: -49.35%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $32.30
Upside: +2.17%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $164.98
Upside: +15.17%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $100.79
Upside: -0.78%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $20.23
Upside: -6.08%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $394.81
Upside: -1.22%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $76.66
Upside: -28.25%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $102.02
Upside: -46.09%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $145.49
Upside: +9.97%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $572.77
Upside: +16.98%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $7.09
Upside: +182.09%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,414.86
Upside: -1.05%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.39
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $48.03
Upside: +87.38%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $226.25
Upside: +19.34%